MedTrace Logo

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

NCT06190067 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-01-30

No results posted yet for this study

Summary

The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.

Conditions

  • Relapsed Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma

Interventions

DRUG

Azacitidine Plus PD-1 therapy

Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)

Sponsors & Collaborators

  • Navy General Hospital, Beijing

    lead OTHER

Principal Investigators

  • Liren Qian, PhD · Navy General Hospital, Beijing

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190067 on ClinicalTrials.gov